|
1
|
GoMiner: a resource for biological interpretation of genomic and proteomic data.
|
Genome Biol
|
2003
|
22.63
|
|
2
|
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.
|
Cancer Cell
|
2004
|
3.72
|
|
3
|
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.
|
Proc Natl Acad Sci U S A
|
2003
|
3.66
|
|
4
|
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics.
|
BMC Bioinformatics
|
2004
|
3.65
|
|
5
|
Karyotypic complexity of the NCI-60 drug-screening panel.
|
Cancer Res
|
2003
|
3.42
|
|
6
|
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells.
|
Genome Biol
|
2003
|
2.52
|
|
7
|
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance.
|
Cancer Res
|
2004
|
2.10
|
|
8
|
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.
|
Cancer Res
|
2003
|
1.51
|
|
9
|
Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.
|
J Surg Oncol
|
2011
|
1.48
|
|
10
|
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
|
Mol Cancer Ther
|
2006
|
1.41
|
|
11
|
Adrenocortical cancer.
|
Surg Clin North Am
|
2009
|
1.17
|
|
12
|
Multifactorial regulation of E-cadherin expression: an integrative study.
|
Mol Cancer Ther
|
2010
|
0.97
|
|
13
|
Isotropic 3D nuclear morphometry of normal, fibrocystic and malignant breast epithelial cells reveals new structural alterations.
|
PLoS One
|
2012
|
0.97
|
|
14
|
PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
|
Surgery
|
2013
|
0.95
|
|
15
|
Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
|
World J Surg
|
2014
|
0.95
|
|
16
|
Targeted therapies for adrenocortical carcinoma: IGF and beyond.
|
Horm Cancer
|
2011
|
0.91
|
|
17
|
Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
|
Ann Surg
|
2012
|
0.78
|
|
18
|
A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma.
|
Pharmacogenomics
|
2012
|
0.77
|
|
19
|
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
|
Cancer Cell
|
2016
|
0.76
|
|
20
|
Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimen repository.
|
Pancreas
|
2010
|
0.75
|